An update on the evidence for FORXIGA(dapagliflozin) in T2D, CKD and HF

You are invited to attend from a selection of expert-led live webinars to learn about the updates to Forxiga’s (dapagliflozin) evidence and indications in: T2D, proteinuric CKD and HFrEF.

Click here for more information and to register.